Abstract
18F-FDG PET/CT has been described as an accurate tool for initial diagnosis of pancreatic adenocarcinoma. It differentiates benign from malignant causes; detects local and, especially, distant spread of disease; and is a very good predictor of patient prognosis. Pancreatic neuroendocrine tumors are rare tumors that originate from the islet cells of the pancreas. Currently, 68Ga-DOTA-labeled somatostatin analogs are considered the best modality for detection of well-differentiated neuroendocrine tumors. 18F-FDG PET/CT has a role in patients with poorly differentiated tumors. Recent studies have demonstrated improved survival in patients with metastatic neuroendocrine tumors treated with radiolabeled somatostatin analogs.
Original language | English (US) |
---|---|
Pages (from-to) | 407-421 |
Number of pages | 15 |
Journal | PET Clinics |
Volume | 12 |
Issue number | 4 |
DOIs | |
State | Published - Oct 2017 |
Keywords
- PET
- PET/CT
- Pancreatic adenocarcinoma
- Pancreatic cancer
- Pancreatic neuroendocrine tumor
ASJC Scopus subject areas
- Radiation
- Radiology Nuclear Medicine and imaging